Targeting HER-2/neuin Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Dendritic cells as therapeutic vaccines against cancer

2005 • 1,195 citations

Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

2000 • 1,175 citations

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

2005 • 1,142 citations

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1999 • 650 citations

The use of dendritic cells in cancer immunotherapy

2003 • 641 citations

Extent, distribution, and mammographic/ histological correlations of breast ductal carcinoma in situ

1990 • 570 citations

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

1995 • 542 citations

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

2002 • 426 citations

High-level IL-12 production by human dendritic cells requires two signals

1998 • 424 citations

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

2001 • 366 citations

Constraints on CD4 Recovery Postchemotherapy in Adults: Thymic Insufficiency and Apoptotic Decline of Expanded Peripheral CD4 Cells

1997 • 334 citations

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

1997 • 195 citations

First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer

2001 • 194 citations

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

2005 • 183 citations

Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas

1999 • 176 citations

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8⁺T-Cell Function in Melanoma Patients

2003 • 169 citations

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

2001 • 157 citations

Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

1997 • 157 citations

Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism

2003 • 139 citations

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

2002 • 136 citations

Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast

2005 • 136 citations

Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines

2003 • 128 citations

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

2000 • 127 citations

Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition

2006 • 126 citations

Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas

2005 • 95 citations

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

1998 • 94 citations

Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent

2004 • 91 citations

Immunogenic HER-2/neu peptides as tumor vaccines

2005 • 76 citations

Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma

2003 • 68 citations

The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

2001 • 65 citations

Microcalcifications on postoperative mammograms as an indicator of adequacy of tumor excision.

1993 • 62 citations

Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes

2004 • 61 citations

HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice

2003 • 60 citations

Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells

2004 • 51 citations

The diagnosis and management of pre-invasive breast disease: Radiological diagnosis

2003 • 49 citations

HER2 Dendritic Cell Vaccines

2003 • 34 citations

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors

2005 • 24 citations

The identification of cancer antigens: impact on the development of cancer vaccines.

2000 • 17 citations

New Target Antigens for Cancer Immunoprevention

2005 • 16 citations

Prognostic significance of lymphoid infiltration in cerebral malignant gliomas.

1990 • 7 citations

Trastuzumab Faces Trials, Clinical and Otherwise

2006 • 3 citations

Cited By (0)

No citing papers found in database